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TPE2
ECONOMIC EVALUATION OF ENOXAPARIN
AS POST DISCHARGE PROPHYLAXIS FOR 
DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE 
HIP SURGERY
Davies LM1, Richardson GA1, Cohen AT2
1Centre for Health Economics, University of York, York, UK; 
2Department of Medicine, Guys, Kings, Thomas’s School of 
Medicine and Dentistry, Denmark Hill, London, UK
OBJECTIVES: Previous research suggests heparin to pre-
vent DVT following orthopaedic surgery is value for
money. Recent trials indicate that extending the duration
of prophylaxis may prevent additional DVT’s, but in-
crease the cost of prophylaxis. The objective of this study
was to compare the expected costs and benefits of using
enoxaparin (a low molecular weight heparin) for the in-
dex hospital admission only versus enoxaparin for hospi-
tal admission and 21 days post discharge.
METHODS: Decision analysis was used to combine prob-
ability, resource use and unit cost data, from the perspec-
tive of the UK NHS and patients. Expected costs and ben-
efits of standard and extended regimes were estimated for
a hypothetical cohort of 1000 patients undergoing elective
hip replacement. Three alternative measures of outcome
were used: lives gained, life years gained and quality ad-
justed life years (QALY) gained. Costs of events were esti-
mated as quantity and type of health care resources used,
multiplied by unit costs. Data for the model was based on
point estimates from a review of clinical and economic lit-
erature. Statistical techniques were not appropriate to as-
sess the level of uncertainty associated with the results.
Sensitivity analysis across minimum and maximum values
of variables was used to test the robustness of the results.
RESULTS: The expected cost per QALY for extended
enoxaparin was £3,145 (range £1268/QALY to £15212/
QALY). Extended enoxaparin was cost saving if 66% of
patients or carers could administer prophylaxis post dis-
charge.
CONCLUSIONS: Whilst conservative data were used to
bias the analysis against extended enoxaparin, limitations
in the data and modelling techniques mean that the results
of the analysis are only indicative of the potential value
for money. The results indicated extended enoxaparin
was associated with a cost/QALY of £1268–£15212,
which compares well with the cost/QALY for other health
care interventions funded by the UK NHS.
TPE3
ECONOMIC EVALUATION OF DIFFERENT 
STRATEGIES OF A VACCINATION AGAINST 
HEPATITIS A AND HEPATITIS B
Smala A1, Berger K1, Szucs T2
1MERG—Medical Economics Research Group, Munich, 
Germany; 2Universitäts Spital Zurich, Zurich, Switzerland
OBJECTIVES: To compare two combined vaccination
strategies against hepatitis A and hepatitis B (at age 1–15
years or at age 11–15 years) with non-vaccination in chil-
dren and youth, to analyse net-costs per strategy, cost-
effectiveness and epidemiologic development in projection
for the next 30 years in Germany.
METHODS: A period of 3 times 10 years is given, model-
ing present data on birth rate development, incidence and
course of disease and treatment costs per case, calculating
incidence, cases of infection resp. disease and treatment
costs, calculated from the TPP’s perspective. Costs per case
and courses were obtained retrospectively from standard-
ized interviews with pediatricians and from the literature.
Cost-effectiveness is assessed as costs per avoided hepatitis
A or hepatitis B infection for each strategy.
RESULTS: Significant drop in HAV and HAB incidence in
vaccinated age groups: Through vaccination of all 1–15
year old children, a reduction of 57 600 new HAV infec-
tions and of 45 800 new HBV infections in 30 years can
be demonstrated. In the vaccination group 11–15 years,
19 800 new infections with HAV and 21 900 new infec-
tions with HBV can be avoided. Vaccination costs over 30
years amount to 1.5 billion DM in the vaccination strategy
11–15 years and 3.7 billion DM in the vaccination strategy
1–15 years. Significant decrease in new infections saves
treatment costs of 1.6 billion DM for the vaccination at age
11–15 years and 2.8 billion DM for the vaccination at age
1–15 years. The cost-effectiveness of vaccination ranges
from costs of 90 100 DM up to savings of - 20 200 DM per
avoided infection, depending on cycle and vaccination strat-
egy. Considering unreported cases of hepatitis A and B as 5
fold of known incidence, the range of savings per avoided
infection is between - 3 300 DM and - 38 700 DM.
CONCLUSION: The initially more expensive combined
vaccine represents a cost-effective alternative to the sole
hepatitis B vaccination and also shows a more beneficial
effect from an epidemiological point of view. In Germany,
the strategy of vaccination between 11–15 years seems to
be the most cost-effective—on the other hand the vaccina-
tion of all between 1–15 years is superior considering the
epidemiological effects.
TPE4
DEVELOPMENT OF A QUALITY ASSESSMENT 
CHECKLIST FOR THE APPRAISAL OF 
ECONOMIC MODELS: A CASE-STUDY
IN OSTEOPOROSIS
Hege U1, Pang F2, Tolley K3
1Department of Health Sciences, University of York, York, 
North Yorkshire, UK; 2Centre for Health Economics, University 
of York, York, North Yorkshire, UK; 3Pfizer Central Research, 
Sandwich, Kent, UK
OBJECTIVES: Deriving data on clinical outcomes to pop-
ulate economic models requires a series of key decisions
upon the part of the economist. Ideally, to minimise the
potential for bias, the process of including data should be
systematic. The objective of this research is to construct a
quality assessment checklist for the inclusion of clinical
and epidemiological data in economic models, and fur-
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thermore to illustrate its application in the area of os-
teoporosis, where economic evaluations predominantly
take the form of decision-analytical models.
METHODS: A systematic review involving electronic da-
tabases and hand-searches was conducted of full economic
evaluations of interventions in osteoporosis. The included
studies were assessed using a checklist based on the Co-
chrane Collaboration handbook for systematic reviews.
The six main items of the checklist included the (i) specifi-
cation of the research question (ii) comprehensiveness of
the literature review (iii) critical appraisal of studies (iv)
relevance of the data extraction (v) appropriateness of the
analysis and (vi) handling of uncertainty.
RESULTS: 18 studies met the criteria for inclusion (UK 
6, US  7, Australia  2). 16 studies considered hormone
replacement therapy, 3 calcitonin, 2 calcium and 2 bisphos-
phonates. It was found that 28% satisfied 4 or more of the
six main criteria. It was also found that only 33% studies
did a comprehensive literature review; primary studies
were predominantly epidemiological, but only 4 appraised
the quality of the observational data.
CONCLUSION: These results demonstrate methodological
weaknesses in the process of including data in osteoporosis
models. Quality checklists for economic models should
therefore emphasise the identification, retrieval, extraction
and pooling methods for the clinical outcome data. Further
there should be increased transparency in the reporting of
economic models to assist in model quality assessment and
validation. Future research should focus on the impact of bi-
ased data selection on cost effectiveness ratios.
TPE5
COST OF MANAGING BENIGN PROSTATE 
HYPERPLASIA IN BELGIUM
Annemans L1,2, Vanoverbeke N2, Closon MC3
1Free University of Brussels, Brussels, Belgium; 2HEDM, 
Mechelen, Belgium; 3Université Catholique de Louvain, 
Brussels, Belgium
OBJECTIVES: To study the cost of illness for patients
newly diagnosed with benign prostate hyperplasia (BPH)
in different scenarios.
METHODS: Published data provide the clinical results of
current relevant management for new BPH patients: al-
pha-blockers (AB), watchful waiting (WW) or surgery (S).
Based on these data, we simulated the history of patients
with moderate BPH in a state transitional model, starting
with one of the three treatment options. The model covers
10 periods of 1 year, and simulates real life treatment
switches (e.g., from WW to AB, from one AB to another,
from WW to S, etc. . .). Ten centres were asked to provide
data on medical management at different states, based on
their local audits. Resulting direct medical costs were cal-
culated from the health care insurance perspective and ap-
plied into the model. Costs were discounted at 3%. The
model was validated by comparison of predicted with ob-
served surgery rates from a National hospital database (68
hospitals).
RESULTS: Patients starting on WW have the lowest cumu-
lative costs (3,750 Euro, SD  3,767 ), followed by patients
starting with AB: 4,559 Euro for tamsulosin (SD  1,702)
and 4,744 Euro for terazosin (SD  1,651). Introducing AB
as second choice after WW has caused an observed reduc-
tion in S rates in Belgium. If AB would not exist, the in-
creased and earlier use of surgery would lead to a predicted
extra cost per patient of 60 Euro per year during the first 5
years, and in the long run to a break-even situation. The
model overestimated observed surgical rates by 4.5%.
CONCLUSIONS: The introduction of AB seems to lead
to a delay of surgery in BPH patients, with short term sav-
ings and long term break-even. The real life short-term
savings may be lower than the predicted, since the model
overestimates the surgical rates.
ECONOMIC OBSERVATIONAL STUDY 
METHODOLOGY ISSUES
TPM1
DIRECT AND INDIRECT COST OF MIGRAINE
IN ITALY
Arpinelli F, Manetta F, Roncolato M, Fabbri L, Rizzini P
Medical Directorate, Glaxo Wellcome S.p.A., Verona, Italy
Migraine has an estimated prevalence of 11.4% in Italy
and is associated with significant morbidity.
OBJECTIVE: To estimate resource consumption (RC) and
costs related to migraine in Italy.
METHODS: This was an observational, multicenter sur-
vey of a patient population attended by general practitio-
ners (GPs). Patients who visited their GPs on five consecu-
tive days of two different weeks were asked if they suffered
from headache. Patients with headache were asked to par-
ticipate in the study if their condition met the International
Headache Society criteria for migraine. Migraineurs re-
ceived a diary in which to record attacks and treatments.
During subsequent GP visits, patients were administered an
RC questionnaire on medical services and lost workdays
due to migraine. Assessment of RC was from the commu-
nity perspective. Values were assigned according to official
sources, and average annual costs in Euro (E) per patient
were calculated.
RESULTS: During the first trimester of 1996, 902 GPs col-
lected data on 71,588 evaluable patients. Prevalence of mi-
graine in the sample was 11.6%. Health care resources (di-
rect costs) accounted for 52.4% of the total annual cost,
while lost workdays (indirect costs) accounted for the re-
maining 47.6%. The total annual cost per migraneur was
E599. Direct costs included: medical consultations E49
(8% of total); tests E63 (11%); drugs E43 (7%); and hospi-
talizations E157 (26%). A total of 2.8 workdays per pa-
tient were lost annually due to migraine. Extrapolated to
the total (active) population in Italy, this corresponds to
15,016,870 lost workdays, amounting to over E1.5 billion
in indirect costs per year. As Italian migraneurs exceed
5,440,000, the total annual cost of migraine in Italy is over
E3.2 billion.
